Back to top
more

AstraZeneca (AZN)

(Delayed Data from NSDQ)

$68.55 USD

68.55
4,735,660

+0.19 (0.28%)

Updated Apr 19, 2024 04:00 PM ET

After-Market: $68.56 +0.01 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 22% (195 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for AZN

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

Fiscal Year End for AstraZeneca PLC falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 6,078 6,492 6,481 8,134 6,254
Receivables 13,552 11,252 10,307 7,386 6,046
Notes Receivable 0 0 0 0 0
Inventories 5,424 4,699 8,983 4,024 3,193
Other Current Assets 0 150 473 0 70
Total Current Assets 25,054 22,593 26,244 19,544 15,563
Net Property & Equipment 9,402 8,507 9,183 8,251 7,688
Investments & Advances 1,905 1,216 1,339 1,318 1,520
Other Non-Current Assets 803 835 895 720 740
Deferred Charges 4,718 3,263 4,330 3,438 2,718
Intangibles 58,137 59,127 62,384 32,792 32,501
Deposits & Other Assets 0 0 0 0 0
Total Assets 101,119 96,483 105,363 66,729 61,377
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 0 0 0
Accounts Payable 22,374 19,040 18,938 15,785 13,987
Current Portion Long-Term Debt 5,129 5,314 1,660 2,194 1,822
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 0 0 0 0 0
Income Taxes Payable 1,584 896 916 1,127 1,361
Other Current Liabilities 1,184 815 847 1,009 759
Total Current Liabilities 30,542 26,293 22,594 20,307 18,117
Mortgages 0 0 0 0 0
Deferred Taxes/Income 2,844 2,944 6,206 2,918 2,490
Convertible Debt 0 0 0 0 0
Long-Term Debt 22,365 22,965 28,134 17,505 15,730
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 5,345 6,498 8,388 9,872 9,957
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 61,953 59,425 66,076 51,091 46,781
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 388 387 387 328 328
Capital Surplus 35,188 35,155 35,126 7,971 7,941
Retained Earnings 1,502 -574 1,710 5,299 2,812
Other Equity 2,088 2,090 2,064 2,040 3,515
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 39,166 37,058 39,287 15,638 14,596
Total Liabilities & Shareholder's Equity 101,119 96,483 105,363 66,729 61,377
Total Common Equity 39,166 37,058 39,287 15,638 14,596
Shares Outstanding 3,100.30 3,099.60 3,098.80 2,624.50 2,623.70
Book Value Per Share 12.63 11.96 12.68 5.96 5.56

Fiscal Year End for AstraZeneca PLC falls in the month of December.

All items in Millions except Per Share data.

3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Assets          
Cash & Equivalents -99,999 6,078 5,212 5,812 6,502
Receivables NA 13,552 11,997 11,932 10,797
Notes Receivable NA 0 0 0 0
Inventories NA 5,424 5,292 5,051 4,967
Other Current Assets NA 0 0 44 0
Total Current Assets NA 25,054 22,501 22,839 22,266
Net Property & Equipment NA 9,402 8,723 8,675 8,644
Investments & Advances NA 1,905 1,441 1,143 1,350
Other Non-Current Assets NA 803 761 752 682
Deferred Charges NA 4,718 4,057 3,736 3,498
Intangibles NA 58,137 57,626 58,286 59,292
Deposits & Other Assets NA 0 0 163 0
Total Assets NA 101,119 96,086 96,543 96,687
Liabilities & Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Notes Payable NA 0 0 0 0
Accounts Payable NA 22,374 20,542 19,738 19,210
Current Portion Long-Term Debt NA 5,129 5,372 4,556 3,625
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 0 0 0 0
Income Taxes Payable NA 1,584 1,163 1,200 1,203
Other Current Liabilities NA 1,184 1,276 650 590
Total Current Liabilities NA 30,542 28,588 26,375 24,860
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 2,844 2,752 2,800 2,795
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 22,365 22,225 24,329 26,916
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 4,556 4,901 5,575
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 61,953 58,865 59,127 60,876
Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 388 387 387 387
Capital Surplus NA 35,188 35,166 35,163 35,159
Retained Earnings NA 1,502 -434 -234 -1,825
Other Equity NA 2,088 2,102 2,100 2,090
Treasury Stock NA 0 0 0 0
Total Shareholder's Equity NA 39,166 37,221 37,416 35,811
Total Liabilities & Shareholder's Equity NA 101,119 96,086 96,543 96,687
Total Common Equity 0 39,166 37,221 37,416 35,811
Shares Outstanding 3,100.40 3,100.30 3,099.80 3,099.70 3,099.70
Book Value Per Share 0.00 12.63 12.01 12.07 11.55